The Claim

Circulating selenoprotein P (SELENOP) concentrations in patients receiving intravenous selenite doses exceeding 1 mg/day increase linearly with baseline plasma selenium levels, but this linear relationship becomes attenuated following prolonged exposure to high-dose selenite, indicating a transition from selenium-dependent synthesis to saturation kinetics.

Source: Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
68score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In patients receiving high-dose intravenous selenite, selenoprotein P levels rise in proportion to baseline selenium in the blood, but this proportional relationship weakens over time due to biological limits in how much selenoprotein P can be produced.

See the scientific wording

Circulating selenoprotein P (SELENOP) concentrations in patients receiving intravenous selenite doses exceeding 1 mg/day show a linear increase with plasma selenium levels at baseline, but this correlation diminishes after prolonged high-dose exposure, suggesting a shift from selenium-dependent synthesis to saturation kinetics.

Why this might work

When large amounts of selenium are given intravenously, the liver converts it into a form that builds more of a protein called SELENOP. Normally, the liver stops making much of this protein after a certain point, but with very high selenium doses, it keeps making even more, pushing the total amount in the blood higher than expected. This happens because the liver's ability to produce SELENOP is not fixed — it can increase its output when there is plenty of selenium available.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

    When people get very high doses of selenium through IV, their SELENOP protein levels keep rising past what scientists thought was the maximum — meaning the body can make more than we used to believe, not that it hits a hard stop.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.